Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
- Conditions
- LymphomaHemophagocytic Lymphohistiocytoses
- Registration Number
- NCT05898477
- Lead Sponsor
- University of Alabama at Birmingham
- Brief Summary
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
- Detailed Description
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2000
- Patients with lymphoma that are fulfilling at least one of the following:
A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)
- Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
- Patients with incomplete treatment and response documentation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+ The participant's survival would be assessed at 180 days from the malignancy diagnosis The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States